Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure

Coronary Heart Disease (JA Farmer, Section Editor)

DOI: 10.1007/s11883-014-0403-7

Cite this article as:
George, J., Struthers, A.D. & Lang, C.C. Curr Atheroscler Rep (2014) 16: 403. doi:10.1007/s11883-014-0403-7
Part of the following topical collections:
  1. Topical Collection on Coronary Heart Disease


The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.


Novel therapy Treatment Drugs Renin-angiotensin-aldosterone blockers Chronic heart failure Reduced/preserved ejection fraction 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Cardiovascular & Diabetes Medicine, Medical Research InstituteUniversity of DundeeDundeeUK
  2. 2.Division of Cardiovascular & Diabetes MedicineMailbox 2, Ninewells Hospital and Medical SchoolDundeeUK

Personalised recommendations